Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study

Woldu, Solomon; Matulay, Justin; Clinton, Timothy; Singla, Nirmish; Freifeld, Yuval; Sanli, Mehmet; Krabbe, Laura-Maria; Hutchinson, Ryan; Lotan, Yair; Hammers, Hans; Hannan, Raquibul; Brugarolas, James; Bagrodia, Aditya; Margulis, Vitaly

doi:10.1016/j.clgc.2018.08.001

Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study

Atıf İçin Kopyala

Woldu S. L., Matulay J. T., Clinton T. N., Singla N., Freifeld Y., Sanli O., ...Daha Fazla

CLINICAL GENITOURINARY CANCER, cilt.16, sa.6, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 16 Sayı: 6
Basım Tarihi: 2018
Doi Numarası: 10.1016/j.clgc.2018.08.001
Dergi Adı: CLINICAL GENITOURINARY CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: Kidney cancer, Surveillance, Systemic therapy, Tyrosine kinase inhibitor, Watchful waiting, ACTIVE SURVEILLANCE, INTERFERON-ALPHA, EFFICACY, WATCH
İstanbul Üniversitesi Adresli: Evet

Özet

The National Cancer Data Base was analyzed to evaluate the impact of delaying initiation of targeted therapy (TT) for metastatic renal-cell carcinoma. After correction for various clinicopathologic factors, delayed initiation of TT was not associated with worse overall survival. This finding supports a practice that appears to be commonplace clinically, although is seldom reported in the literature.